A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer.

Trial Profile

A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sorafenib (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2019.
    • 30 Dec 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017 as per ClinicalTrials.gov record.
    • 25 Aug 2015 Planned number of patients changed from 40 to 42 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top